Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16146754 | 0.85 | GDA (0.39) | LMNAPDPK1ALDH1A1 | |
| SCHEMBL7670280 | 0.81 | PARP1 (0.32) | PARP1 | |
| SCHEMBL29593210 | 0.78 | SYK (0.39) | — | |
| SCHEMBL22939319 | 0.78 | SYK (0.39) | — | |
| SCHEMBL128574 | 0.77 | PDPK1 (0.39) | PDPK1PARP1 | |
| SCHEMBL20093457 | 0.77 | PARP1 (0.32) | PARP1 | |
| SCHEMBL22118770 | 0.76 | BRD4 (0.40) | PARP1BRD4 | |
| SCHEMBL29654971 | 0.76 | BRD4 (0.40) | PARP1BRD4 | |
| SCHEMBL16146540 | 0.74 | CDK2 (0.43) | LMNAPOLBPDPK1 | |
| SCHEMBL12186852 | 0.73 | MAP4K4 (0.35) | PDPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210154221-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-05-27 | — | — | US | disclosed |
| US-10953029-B2 | 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof | MERCK SHARP & DOHME CORP. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3352781-B1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20190022115-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-01-24 | — | — | US | disclosed |
| EP-3352781-A2 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | Merck Sharp & Dohme Corp. (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017053216-A2 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154221-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | HPRT1, SAMHD1, DUT | LMNA 2288/4885POLB 24/4885PDPK1 3687/4885 |
| US-20190022115-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | HPRT1, DUT, SAMHD1 | LMNA 2165/4885POLB 24/4885PDPK1 3771/4885 |
| US-10953029-B2 | 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof | DUT, HPRT1, SAMHD1 | LMNA 2109/4885POLB 23/4885PDPK1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.